ERCC1和 TS 表达对胃癌术后患者改良FOLFOX7方案辅助化疗疗效的预测

目的：探讨切除修复交叉互补基因（ ERCC1）和胸苷酸合成酶（ TS） mRNA在胃癌标本中的表达及其对改良FOLFOX方案辅助化疗疗效的预测。方法采用实时荧光定量PCR法检测73例胃癌根治术患者病变组织中ERCC1和TS mRNA的表达情况，患者均行改良FOLFOX方案辅助化疗，分析ER-CC1和TS两者表达相关性及两者对改良FOLOFX方案辅助化疗疗效的预测。结果胃癌组织中ERCC1高表达率为42．5％（31/73），TS高表达率为61．6％（45/73）。 ERCC1和TS的表达与患者临床特征无相关性，且两者表达无关联性。在本研究中ERCC1低表达的患者中位RFS和MST分别为16个月和27个月，ERCC1高表达患者分别为9个月和16个月，两组中位RFS 和MST 差异均具有统计学意义（ P＝0．000，P＝0．002）。 TS高表达和 TS低表达患者中位RFS，MST 差异均无统计学意义（P＝0．10，P＝0．71）。结论胃癌患者ERCC1的表达水平可以预测FOLFOX辅助化疗方案的疗效，即ERCC1低表达的患者会从中受益。

Predictive values of the expression of ERCC1 and TS for FOLFOX adjuvant chemotherapy in gastric cancer

Objective To study the expression of the excision repair cross complementing 1 （ ERCC1 ） and thymidylate synthase （ TS） in gastric cancer and to investigate the correlation between the ERCC 1 and TS ex-pression with the efficacy of FOLFOX adjuvant chemotherapy in gastric cancer patients .Methods A total of 73 gastric cancer patients received modified FOLFOX adjuvant chemotherapy .Real-time PCR was used to investi-gate the expression of ERCC 1 and TS in gastric cancer tissue .We also studied their correlation and association with prognosis .Results ERCC1 and TS expressed in gastric cancer tissues with the positive rate were 42 .5%（31/73）and 61.6%（45/73）.There was no significant correlation between the ERCC 1 or TS expression and the clinical features .In this study ,the median of RFS and MST were 16 months and 27 months in patients with ER-CC1-negtive expression,9 months and 16months in patients with ERCC1-positive expression,the median of RFS and MST were significantly different in the two groups （P=0.000,P=0.002）.There were no statistical differences on TS expression pattern in either median of RFS or MST （P=0.10,P=0.71）.Conclusion The ex-pression of ERCC1 may be useful in prediction of the clinical outcome in gastric cancer patients who treated with FOLFOX7 adjuvant chemotherapy .Patients with ERCC1-negtive expression may benefit from the therapy .